Moors & Cabot’s Inovio Pharmaceuticals INO Stock Holding History

Moors & Cabot’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-904	Closed	-$39K	–	865
2022 Q1	$39K	Sell	904 -42	-4%	-$1.89K	﹤0.01%	841
2021 Q4	$57K	Sell	946 -358	-27%	-$28.7K	﹤0.01%	838
2021 Q3	$113K	Sell	1,304 -42	-3%	-$4.21K	0.01%	794
2021 Q2	$150K	Buy	1,346 +204	+18%	+$19.6K	0.01%	750
2021 Q1	$127K	Buy	+1,142	New	+$150K	0.01%	714

Other funds holding INO

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return

Moors & Cabot's INO Position: Q2 2022 in Review

Moors & Cabot sold out of Inovio Pharmaceuticals (INO) in Q2 2022, closing a stake of 904 shares — an estimated $39K sold.

Moors & Cabot first reported a position in INO in Q1 2021 and held it in 5 quarters. The position peaked at $150K in Q2 2021. 184 funds tracked by Wall St. Rank hold INO as of Q2 2022.

Moors & Cabot reported no remaining Inovio Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Moors & Cabot sold 904 Inovio Pharmaceuticals shares in Q2 2022, an estimated $39K.
Moors & Cabot first reported a position in Inovio Pharmaceuticals in Q1 2021 and held it in 5 quarters.
Moors & Cabot's Inovio Pharmaceuticals position peaked at $150K in Q2 2021.
184 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2022.

Based on Moors & Cabot's 13F filing for Q2 2022, filed 8 Aug 2022.